Drug Trial Radar · NCT06272747
Study of XH-S003 in Healthy Volunteers
Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Jul 10, 2023
Primary completion
Jul 30, 2024
Study completion Nov 30, 2024
Sponsor
- Lead sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to assess the safety, tolerability and pharmacokinetics of XH-S003 in healthy volunteers under SAD (Single ascending dose) and MAD (Multiple ascending dose) studies. In addition, this study evaluates the food effects of XH-S003.
Conditions
- Healthy Adults
Interventions
XH-S003Drug
IP: XH-S003 Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
PlaceboDrug
Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs)Time frame: Part A: Approximately 1~2 weeks
- Number of participants with adverse events (AEs)Time frame: Part B: Approximately 3~4weeks
- Number of participants with adverse events (AEs)Time frame: Part C: Approximately 3~4weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Friendship Hospital,Capital Medical University
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.